CClinicalTrials.gg
CompletedNCT03436082Updated Mar 19, 2021Results posted

Post-Market Surveillance With a Novel mHealth Platform

An observational study in Gastrectomy and Atrial Fibrillation, sponsored by Yale University. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-03-19.

Sponsored by Yale University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Study summary

This is a study to pilot the feasibility of using a novel patient-led, smartphone-based mobile health platform (Hugo) for real-world surveillance of outcomes of patients after they undergo a bariatric surgical procedure (either sleeve gastrectomy or gastric bypass) and catheter-based atrial fibrillation ablation

Read the detailed description

The plan is to pilot test a novel patient-led, smartphone-based mobile health platform (called Hugo) for real-world surveillance of outcomes in 60 total patients after medical device use. Research associates will be recruiting patients before they undergo a bariatric surgical procedure (either sleeve gastrectomy or gastric bypass) and catheter-based atrial fibrillation ablation. Patients will then be queried about specific symptoms related to their procedure. Patients will also be given syncable devices to use that will provide additional insights into their health and health outcomes. This pilot project will engage patients to report outcomes while also synchronizing data from their electronic health records and pharmacy accounts to ascertain the ability of emerging mobile health technologies to aid in post-marketing surveillance.

02

Conditions studied

  • Gastrectomy
  • Atrial Fibrillation

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A patient's eligibility will first be determined by the implanting physician who will be performing the catheter-based atrial fibrillation ablation or bariatric surgical procedure (either sleeve gastrectomy or gastric bypass). The criterion used will simply be the cardiac electrophysiologist stating that the patient is being seen pre-procedurally for catheter ablation of atrial fibrillation or the bariatric surgeon stating that the patient is being seen pre-operatively for sleeve gastrectomy or gastric bypass.

Inclusion criteria

  • Age >18
  • English-speaking
  • Planned for either a bariatric surgical procedure (either sleeve gastrectomy or gastric bypass) or catheter-based atrial fibrillation ablation
  • Participant is willing and able to read and sign consent and participate in study
  • Participant has an email account and a mobile device (smartphone or tablet) able to download the necessary applications
  • Participant is willing to use the mobile health platform and syncable devices (e.g. Fitbit Charge 2)
  • Attending bariatric surgeon or electrophysiologist (as appropriate) concurs that patient is a candidate for enrollment

Exclusion criteria

Exclusion Criteria:

Healthy patients

Patients who refuse participation

04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (actual)
Target follow-up
8 Weeks
Patient registry
Yes

Groups and cohorts

  • Data from a mHealth platform after bariatric surgery

    Patients that have undergone sleeve gastrectomy or gastric bypass will pilot test the use of the patient-led, smartphone based, mhHealth platform HUGO.

    Device: A mobile health platform

  • Data from a mobile health platform after atrial fibrillation

    Patients that have undergone a catheter-based atrial fibrillation ablation will pilot test the use of the patient-led, smartphone based, mobile health platform HUGO.

    Device: A mobile health platform

Interventions

  • DeviceA mobile health platform

    Patients pilot testing the smartphone based, mobile health platform called HUGO. Patients will also be given syncable devices to use that will provide additional insights into their health and health outcomes.Patients will be queried about specific symptoms related to their procedure at enrollment, one week post-procedure, at 4 weeks and again at 8 weeks.

05

What researchers measure

Primary outcomes

  1. Number of Disease-Specific PROMs Completed

    Disease-specific PROMs were collected using email notification to all patients over the course of the study. Disease-specific PROMs were emailed to patients at enrollment (preprocedure) and 1, 4, and 8 weeks post-procedure and were tailored to patients depending on the procedure they received. For each PROM, the date and time that it was emailed to patients, the time it was initiated, and the time at which the final response was received were all available.

    Time frame: 8 weeks

  2. Number of Post-Procedure PROMs Completed

    Post-procedure PROMs were collected using email notification to all patients over the course of the study. Post-procedure PROMs were emailed to patients twice weekly for a total of 5 weeks post-procedure. Bariatric surgery patients were asked two questions: (1) if they had pain (yes/no) and, if yes, to rate their pain on a scale of 1-10 and (2) if they had an appetite (yes/no) and, if yes, to rate their appetite on a scale of 1-10. Atrial fibrillation ablation patients were asked about pain, as well as whether they had palpitations and, if yes, to rate both symptoms on a scale of 1-10. For each PROM, the date and time that it was emailed to patients, the time it was initiated, and the time at which the final response was received were all available.

    Time frame: 5 weeks

  3. Device Syncs

    Device syncs are operationally defined as the # of patients who synced their device at all required time points over the 8-week post-procedure period.

    Time frame: 8 weeks

  4. Electronic Health Record Data Validation

    For EHR data, we validated the following components over 8 weeks follow-up: encounter date, encounter type, and encounter primary diagnosis. Specifically, we determined if encounters aggregated by the patient-centered health data sharing platform, Hugo, matched encounters listed in each patient's EHR.

    Time frame: 8 weeks

06

Results

Posted Mar 19, 2021
Limitations and caveats
Enrolled a small number of patients (60) for a relatively short follow-up duration (8 weeks); EHR data for 5 patients were not observable in Hugo due to sync failure after portals were locked out from multiple incorrect password entries or an EHR upgrade; Stipends were provided to cover time and effort involved with study enrollment and participation and free personal digital devices, both of which may have enhanced engagement over the follow-up period; Did not examine quality of data obtained

Participant flow

Participant flow — Overall Study
MilestoneBariatricAF Ablation
Started3030
Completed2930
Not completed10
Withdrew: Did not undergo procedure10

Outcome measures

PrimaryNumber of Disease-Specific PROMs Completed

Disease-specific PROMs were collected using email notification to all patients over the course of the study. Disease-specific PROMs were emailed to patients at enrollment (preprocedure) and 1, 4, and 8 weeks post-procedure and were tailored to patients depending on the procedure they received. For each PROM, the date and time that it was emailed to patients, the time it was initiated, and the time at which the final response was received were all available.

Time frame:
8 weeks
Reported as:
Number · # PROMs completed
Number of Disease-Specific PROMs Completed
# PROMs completedBariatricAF Ablation
Number of Disease-Specific PROMs Completed6459
Statistical analysis
  • Bariatric vs AF Ablation · Chi-squared · p = 0.04
PrimaryNumber of Post-Procedure PROMs Completed

Post-procedure PROMs were collected using email notification to all patients over the course of the study. Post-procedure PROMs were emailed to patients twice weekly for a total of 5 weeks post-procedure. Bariatric surgery patients were asked two questions: (1) if they had pain (yes/no) and, if yes, to rate their pain on a scale of 1-10 and (2) if they had an appetite (yes/no) and, if yes, to rate their appetite on a scale of 1-10. Atrial fibrillation ablation patients were asked about pain, as well as whether they had palpitations and, if yes, to rate both symptoms on a scale of 1-10. For each PROM, the date and time that it was emailed to patients, the time it was initiated, and the time at which the final response was received were all available.

Time frame:
5 weeks
Reported as:
Number · # PROMs completed
Number of Post-Procedure PROMs Completed
# PROMs completedBariatricAF Ablation
Number of Post-Procedure PROMs Completed203237
PrimaryDevice Syncs

Device syncs are operationally defined as the # of patients who synced their device at all required time points over the 8-week post-procedure period.

Time frame:
8 weeks
Reported as:
Number · # patients who synced at all time points
Device Syncs
# patients who synced at all time pointsBariatricAF Ablation
Fitbit1714
Disease-Specific (Withings Body Scale/Kardia Mobile)1115
Statistical analysis
  • Bariatric vs AF Ablation · Chi-squared · p = 0.85
PrimaryElectronic Health Record Data Validation

For EHR data, we validated the following components over 8 weeks follow-up: encounter date, encounter type, and encounter primary diagnosis. Specifically, we determined if encounters aggregated by the patient-centered health data sharing platform, Hugo, matched encounters listed in each patient's EHR.

Time frame:
8 weeks
Reported as:
Number · Number of matched records
Electronic Health Record Data Validation
Number of matched recordsBariatricAF Ablation
Encounter Date105110
Encounter Type103100
Primary Diagnosis103101

Adverse events

Collected over 8 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bariatric0/29 (0%)0/29 (0%)0/29 (0%)
AF Ablation0/30 (0%)0/30 (0%)0/30 (0%)

Baseline characteristics

We enrolled a convenience sample of patients who were planning on undergoing either bariatric surgery (sleeve gastrectomy and gastric bypass) or catheter-based atrial fibrillation ablation at Yale-New Haven Hospital (YNHH) or the Mayo Clinic. 15 patients were enrolled for each procedure at each site, for a total of 60 patients.

Age, Categorical
Age, Categorical(Participants)BariatricAF AblationTotal
<=18 years000
Between 18 and 65 years271643
>=65 years31417
Age, Continuous
Age, Continuous(Years)BariatricAF AblationTotal
Mean46.4 ± 12.562.4 ± 1055.2 ± 13.5
Sex: Female, Male
Sex: Female, Male(Participants)BariatricAF AblationTotal
Female231235
Male71825
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)BariatricAF AblationTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)BariatricAF AblationTotal
United States303060
07

Study locations

2 sites
  • Yale New Haven Hospital
    New Haven, Connecticut 06510, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
08

References and documents

Publications

  • Dhruva SS, Ross JS, Akar JG, Caldwell B, Childers K, Chow W, Ciaccio L, Coplan P, Dong J, Dykhoff HJ, Johnston S, Kellogg T, Long C, Noseworthy PA, Roberts K, Saha A, Yoo A, Shah ND. Aggregating multiple real-world data sources using a patient-centered health-data-sharing platform. NPJ Digit Med. 2020 Apr 20;3:60. doi: 10.1038/s41746-020-0265-z. eCollection 2020. PubMed 32352038 ↗
  • Bartlett VL, Ross JS, Shah ND, Ciaccio L, Akar JG, Noseworthy PA, Dhruva SS. Physical activity, patient-reported symptoms, and clinical events: Insights into postprocedural recovery from personal digital devices. Cardiovasc Digit Health J. 2021 Jul 3;2(4):212-221. doi: 10.1016/j.cvdhj.2021.06.002. eCollection 2021 Aug. PubMed 35265911 ↗

Study documents

  • Study protocol · Sep 24, 2018

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT03436082
Lead sponsor
Yale University
Collaborators
Johnson & Johnson, Food and Drug Administration (FDA), Mayo Clinic
Responsible party
Sponsor
First posted
Feb 19, 2018
Start date
Jan 26, 2018
Primary completion
Dec 25, 2018
Completion
Dec 25, 2018
Results posted
Mar 19, 2021
Last update
Mar 19, 2021

Study contacts

Joseph Ross, MD
principal investigator · Yale University
Sanket Dhruva, MD
principal investigator · Yale University
Nilay Shah, PhD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion